Aquestive Therapeutics (NASDAQ:AQST) Trading Down 5.9% – Time to Sell?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) shares traded down 5.9% during mid-day trading on Monday . The company traded as low as $5.77 and last traded at $5.6850. 1,451,721 shares changed hands during mid-day trading, a decline of 26% from the average session volume of 1,970,004 shares. The stock had previously closed at $6.04.

Analysts Set New Price Targets

Several research firms recently issued reports on AQST. JMP Securities raised their price objective on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 9th. Citigroup reissued an “outperform” rating on shares of Aquestive Therapeutics in a research note on Thursday, October 9th. Lifesci Capital raised shares of Aquestive Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 3rd. Oppenheimer upped their price objective on Aquestive Therapeutics from $7.00 to $8.00 and gave the company an “outperform” rating in a report on Monday, September 8th. Finally, Piper Sandler increased their price objective on Aquestive Therapeutics from $5.00 to $8.00 and gave the stock an “overweight” rating in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $10.00.

Aquestive Therapeutics Stock Performance

The stock’s 50-day moving average is $5.88 and its two-hundred day moving average is $4.29. The stock has a market cap of $680.76 million, a PE ratio of -7.86 and a beta of 1.79.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The business had revenue of $12.81 million during the quarter, compared to the consensus estimate of $12.94 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Insider Transactions at Aquestive Therapeutics

In other news, CEO Daniel Barber sold 91,343 shares of the stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $6.03, for a total transaction of $550,798.29. Following the sale, the chief executive officer owned 923,430 shares of the company’s stock, valued at approximately $5,568,282.90. This represents a 9.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Carl N. Kraus sold 20,272 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $7.00, for a total transaction of $141,904.00. Following the completion of the transaction, the insider directly owned 282,475 shares of the company’s stock, valued at approximately $1,977,325. The trade was a 6.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 276,770 shares of company stock valued at $1,692,203. Insiders own 7.85% of the company’s stock.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of hedge funds have recently added to or reduced their stakes in AQST. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Aquestive Therapeutics in the first quarter worth $33,000. SBI Securities Co. Ltd. boosted its holdings in Aquestive Therapeutics by 47.0% in the first quarter. SBI Securities Co. Ltd. now owns 47,553 shares of the company’s stock valued at $138,000 after purchasing an additional 15,205 shares during the period. Victory Capital Management Inc. purchased a new position in Aquestive Therapeutics in the first quarter valued at $31,000. Summit Wealth & Retirement Planning Inc. acquired a new position in Aquestive Therapeutics during the 1st quarter worth $29,000. Finally, Dauntless Investment Group LLC purchased a new stake in Aquestive Therapeutics during the 1st quarter worth about $265,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.